Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8926627 | 0.97 | DNM1 (0.46) | LMNATSHRTHRBDNM1OPRM1 | |
| SCHEMBL6870580 | 0.89 | DNM1 (0.39) | LMNATSHRTHRBDNM1OPRM1 | |
| SCHEMBL8927188 | 0.84 | DNM1 (0.36) | LMNATSHRDNM1FDPS | |
| SCHEMBL11940481 | 0.81 | OPRM1 (0.31) | OPRM1 | |
| SCHEMBL1311334 | 0.78 | TSHR (0.47) | LMNATSHRTHRBDNM1OPRM1 | |
| SCHEMBL1932599 | 0.78 | TSHR (0.47) | LMNATSHRTHRBDNM1OPRM1 | |
| SCHEMBL3793621 | 0.78 | TSHR (0.47) | LMNATSHRTHRBDNM1OPRM1 | |
| SCHEMBL3795488 | 0.78 | TSHR (0.47) | LMNATSHRTHRBDNM1OPRM1 | |
| SCHEMBL1931400 | 0.78 | TSHR (0.47) | LMNATSHRTHRBDNM1OPRM1 | |
| SCHEMBL3799758 | 0.78 | TSHR (0.47) | LMNATSHRTHRBDNM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002313-A1 | [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2024-01-04 | — | — | US | disclosed |
| EP-4249058-A1 | [11C]-LABELLED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | National Center for Geriatrics and Gerontology (JP) | 2023-09-27 | — | — | EP | disclosed |
| US-5600034-A | HEAT TREATING DIALLYL ETHERS IN PRESENCE OF CATALYST CONTAINING PALLADIUM AND PHOSPHORUS COMPOUNDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-02-04 | — | — | US | disclosed |
| US-5583271-A | Method for continuously producing alkadienols | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002313-A1 | [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | NR2E3, FABP7, RARB | LMNA 4543/4885TSHR 8/4885THRB 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.